Daniel
Almonacid
Santiago, Chile; and San Diego, California
CEO of DrugBiome. Previously I was CSO at Digbi Health, Head of Data Science and Product Development at Biome Makers, SVP of Science and Innovation at uBiome, Adjunct Professor of Bioinformatics at U. Andres Bello, postdoc in bioengineering and therapeutic sciences at UCSF, PhD in molecular informatics for the U. of Cambridge. Cofounder of a few startups, advisor.
The drug development industry has largely overlooked the role of the commensal microbiota in human health. We will leverage the current knowledge of the microbiome together with advancements in protein structure prediction to systematically uncover bacterial targets for drug development. Initially, these efforts will improve the efficacy of FDA-approved drugs or those that were safe but failed in phase 2 or 3 clinical trials. In the long term, this approach will deliver targets and drugs for health conditions lacking current therapeutic interventions.
Leadership, management, brain circulation, marketing, fostering innovation.
I am the scientist with the most patents in the microbiome field worldwide.